日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data

使用 BCR-ABL 酪氨酸激酶抑制剂治疗肺动脉高压的风险:利用全国数据优化风险评估

Garry, Jonah D; Brittain, Evan L

Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design

第二代和第三代 BCR-ABL 酪氨酸激酶抑制剂与肺动脉高压风险:一项针对新用户的普遍研究

Jambon-Barbara, Clément; Suissa, Samy; Dell'Aniello, Sophie; Hlavaty, Alex; Cracowski, Jean-Luc; Chaumais, Marie-Camille; Humbert, Marc; Montani, David; Khouri, Charles

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2(+) breast cancer: TBCRC049 phase 2 study results

Tucatinib-trastuzumab-capecitabine治疗HER2(+)乳腺癌女性软脑膜转移:TBCRC049 II期研究结果

Murthy, Rashmi K; O'Brien, Barbara J; Berry, Donald A; Singareeka-Raghavendra, Akshara; Monroe, Maria Gule; Johnson, Jason; White, Jason; Schwartz-Gomez, Jill; Topletz-Erickson, Ariel; Lobbous, Mina; Riley, Kristen; Melisko, Michelle; Morikawa, Aki; Ferguson, Sherise D; de Groot, John F; Krop, Ian E; Valero, Vicente; Rimawi, Mothaffar F; Wolff, Antonio C; Tripathy, Debu; Lin, Nancy U; Stringer-Reasor, Erica M

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second-line therapy in pediatric chronic myeloid leukemia

儿童慢性粒细胞白血病二线治疗后BCR::ABL1转录水平的动态变化及临床结局

Sembill, Stephanie; Zerjatke, Thomas; Winterstein, Micha; Ghete, Tabita; Schirmer, Elke; Wotschofsky, Zofia; Suttorp, Meinolf; Krumbholz, Manuela; Karow, Axel; Glauche, Ingmar; Metzler, Markus

Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow

在剂量递减期间,对外周血进行连续的 BCR::ABL1 评估比在剂量递减时对外周血或骨髓进行单次评估更能预测无治疗反应 (TFR) 的成功率。

Patterson, S D; Gottschalk, A; Hayden, C; Young, R; Hair, A; Jørgensen, H G; Wheadon, H W; Apperley, J F; Glauche, I; Clark, R E; Copland, M; Roeder, I

BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβ

BCR-ABL1通过C/EBPβ驱动慢性粒细胞白血病细胞的转录重编程以实现免疫逃逸

Lu, Xiaocui; Fang, Hui; Liu, Yuan; Liu, Chang; Fang, Xuexiu; Matsunaga, Atsuko; Mori, Stephanie F; Zhang, Ting; Wang, Gavin; Zhou, George I; Yu, Miao; Ding, Haocheng; Cortes, Jorge; Cheng, Bo; Hu, Tianxiang

Inhibition of autoantigen-induced B-cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)

抑制自身抗原诱导的B细胞受体(BCR)内化作为弥漫性大B细胞淋巴瘤(DLBCL)的治疗策略

Górniak, Patryk; Polak, Anna; Rams, Anna; Kupcova, Kristyna; Głodkowska-Mrówka, Eliza; Pilch, Zofia; Miączyńska, Marta; Nowis, Dominika; Gołąb, Jakub; Davis, R Eric; Havranek, Ondrej; Juszczyński, Przemysław

Failure of early B cell tolerance and possible BCR signaling dysregulation underlie NF155-mediated autoimmune nodopathies

早期B细胞耐受失败和可能的BCR信号传导失调是NF155介导的自身免疫性结节病的基础。

Roy, Bhaskar; Obaid, Abeer H; Wang, Zhenjian; Kovacs, Kristof G; Ohashi, Sarah; Kalayci, F Naz Cemre; Joo, Daniel; Masi, Gianvito; Coppola, Carmina; Das, Sameeran; Hernandez, Amanda L; Martin-Aguilar, Lorena; Lleixà, Cinta; Nowak, Richard J; Querol, Luis; O'Connor, Kevin C

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer

TBCRC 035:一项随机 II 期药效学研究,评估标准剂量和减量帕博西尼联合内分泌治疗在激素受体 (HR) 阳性、既往接受过治疗的转移性乳腺癌患者中的疗效

Jacob, S; Mayer, E L; Kacik, N; Storniolo, A M; Isaacs, C; Mayer, I; Stearns, V; Nanda, R; Nangia, J; Chien, A J; Moasser, M; Melisko, M; Wabl, C; Muzikansky, A; Geradts, J; Dillon, D A; Park, B H; Krop, I; Wolff, A C; Kochupurakkal, B; Shapiro, G I; Rugo, H S

Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study

一例伴有非典型 BCR::ABL1 e13a3 转录本的慢性粒细胞白血病患者出现原发性 asciminib 耐药:病例研究

Jung, Birte Kristin; Weißmann, Sandra; Schock, Caroline; Meggendorfer, Manja; Haferlach, Torsten; Dicker, Frank